Decoy Therapeutics Inc.
corporate_fare Company Profile
Decoy Therapeutics Inc. (NASDAQ:DCOY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 22 items for DCOY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 14 rated 8 or above. Recent SEC coverage for DCOY spans S-3, 10-Q, 424B3, S-1.
Recent high-impact activity:
- Decoy Files $50M Shelf While Carrying Going-Concern Warning and Nasdaq Delisting Risk
- Decoy Therapeutics Posts $3.53/Share Loss, Missing $2.59 Estimate
- Decoy Therapeutics Q3 10-Q: Going Concern, $8.2M Cash, New Nasdaq Delisting Risk
- Decoy's 2.37M-Share Armistice Resale Registration Goes Effective; Cash Runs to Early 2027
- Decoy Files S-1 to Register Resale of 2.37 Million Shares Underlying Armistice Warrants
Financial Snapshot
Short Interest & Short Volume
1.82 days to coverFINRA reported short interest of 99,728 shares in DCOY as of the October 30, 2026 settlement, a 2.2% increase from the prior period — about 1.8 days to cover at its recent average daily volume. On November 20, 2026, 37.4% of DCOY volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for DCOY, detected from its recent SEC filings · based on capital-structure filings through 2026-07-24.
Warrant Exercise Vote Sought · Massive Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →